Extended Data Fig. 6: Baseline prognostic values and landmark RFS analysis. | Nature Medicine

Extended Data Fig. 6: Baseline prognostic values and landmark RFS analysis.

From: Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Extended Data Fig. 6

a-e, RFS from study start (date of first vaccine dose) stratified by a, tumor stage at baseline, n = 25, b, absolute lymphocyte count in peripheral blood at baseline, n = 25, c, absolute neutrophil count in peripheral blood at baseline, n = 25, d, %CD4+ among CD3+ lymphocytes at baseline among ICS evaluable patients, n = 22, e, %CD8+ among CD3+ lymphocytes at baseline among ICS evaluable patients, n = 22. f, RFS from landmark (completion of prime immunization) stratified by T cell response (Maximum fold change from baseline; ≥ Median versus < Median) among evaluable patients with RFS exceeding the landmark as of the data cut-off, n = 22. n indicates individual patients. HR indicates hazard ratio with 95% CI. P values calculated using two-tailed log-rank test.

Back to article page